Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03452514 |
Recruitment Status :
Completed
First Posted : March 2, 2018
Last Update Posted : February 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Lung Cancer |
This is a prospective, longitudinal, blinded, observational diagnostic study on 400 individuals undergoing lung cancer screening with low-dose computed tomography (LDCT).
There will be two patient cohorts: Cohort 1: individuals undergoing their first or subsequent annual LDCT screening study; and Cohort 2: individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan.
At study enrollment a blood sample will be drawn prior to the LDCT scan. On this blood sample a novel lung cancer test relying on microRNA signatures will be evaluated. The results will be compared with the CT scan results and follow-up tests including pathology. Histologic results and follow-up data will be collected on all patients for a minimum of 12 months post-enrollment. During the follow-up period, the results of all diagnostic chest CT scans, lung biopsies or lung resections will be captured from the Partners electronic medical record and entered into the case report form (CRF).
Study Type : | Observational |
Actual Enrollment : | 479 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Prospective Longitudinal Blinded Observational Diagnostic Study - Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT |
Actual Study Start Date : | November 1, 2017 |
Actual Primary Completion Date : | September 14, 2020 |
Actual Study Completion Date : | September 15, 2020 |
Group/Cohort |
---|
Cohort 1 - Low Dose CT (LDCT) Scan
Individuals undergoing their first or subsequent annual LDCT screening study
|
Cohort 2 - Diagnostic CT Scan
Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
|
- Specificity of HMBDx microRNA Test for Lung Cancer [ Time Frame: 12 months ]The reference standard will be the combination of all available diagnostic information (LDCT, subsequent diagnostic imaging studies, biopsy results and surgical pathology results) obtained during at least 12 months of follow-up.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Subject is undergoing LDCT screening for lung cancer.
- Subject is 55 to 80 years of age.
- Subject has a minimum 30 pack-year smoking history.
- Subject has not quit smoking more than 15 years ago.
- Subject is without symptoms attributable to lung cancer.
- Subject is able and willing to provide informed consent.
Exclusion Criteria:
- Subject has a history of lung, gastrointestinal, hematological, breast, thyroid, or genitourinary cancers within the past ten years.
- Subject is known to be infected with HIV, HBV, HCV, or tuberculosis or any other Biosafety Level 3 (BSL III) pathogen infections.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03452514
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
Brigham and Women's Hospital | |
Boston, Massachusetts, United States, 02115 | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 | |
Lahey Hospital & Medical Center | |
Burlington, Massachusetts, United States, 01805 |
Study Director: | Amita Sharma, MD | Massachusetts General Hospital |
Responsible Party: | Hummingbird Diagnostics |
ClinicalTrials.gov Identifier: | NCT03452514 |
Other Study ID Numbers: |
HMBDx USA-0001 |
First Posted: | March 2, 2018 Key Record Dates |
Last Update Posted: | February 25, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |